Key Metrics
Q4
Mathematics (all)
SJR
- Q4 Mathematics (all)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
Topics Covered
- Antitumor response
- Immune modulation
- Clinical trial
- VLA-4
- Metabolic reprogramming
- Antigen
- B-cell lymphoma
- Monoclonal antibody
- Chimeric antigen receptor
- Cancer immunotherapy
- Steady state
Journal Specifications
| Overview | |
| Publisher | Oxford University Press |
| Language | English |
| Article Processing Charges | GBP 2100 |
| Publication Time | 7 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | British Society for Immunology |
| Website URL | Visit website |
| Publication Details | |
| Waiver Policy | Visit website |
| Publication Time | 7 |
| Article Processing Charges | GBP 2100 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
Planning to publish in Immunotherapy Advances ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
Establishment of Humanised Xenograft Models as <i>In Vivo</i> Study for Lung Metastasis of Osteosarcoma
- 23 Mar 24
- Immunotherapy Advances
-
Full paper
Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study.
- 1 Jan 24
- Immunotherapy advances
-
Full paper
Cancer vaccines: from an immunology perspective.
- 21 Dec 23
- Immunotherapy advances
-
Full paper
Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira® or undergoing repeated switches between Humira® and AVT02.
- 21 Dec 23
- Immunotherapy advances
-
Full paper
Harnessing natural killer cell effector function against cancer.
- 21 Dec 23
- Immunotherapy advances
-
Full paper
Strategies to overcome low MHC-I expression in paediatric and adult tumours.
- 11 Dec 23
- Immunotherapy advances
Scite analysis
Powered by scite_
95 articles received 276 citations see all
- 3 Supporting
- 272 Mentioning
- 1 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 6 Corrections
- 2 Errata
- 0 Expression of Concern
FAQs
How many articles did Immunotherapy Advances publish last years ?
In 2023, Immunotherapy Advances published 32 articles.
What is the SJR for Immunotherapy Advances ?
SJR for Immunotherapy Advances is Q4.
Who is the publisher of Immunotherapy Advances ?
Oxford University Press is the publisher of Immunotherapy Advances.